Holly Bastian, MD
Rheumatology · Rockwall, TXNPI 1588619043
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 28.5% of the total. Reporting peaked in 2019 at $430 and has fallen 95.6% since, to $19 in 2025. That places this record below the midpoint for rheumatology clinicians in TX, where the typical reported total is $3,779.
Across 36 payments — averaging $25.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$257
- GSK$162
- Amgen$85
- E.r. Squibb & Sons, L.L.C.$66
- AstraZeneca$51
- Xeris Pharmaceuticals, Inc.$45
- plus $236 from 10 others
What the payments were for
- Food & beverage$89599%
- Education$71%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 8 | $257 |
| GSK | 2 | $162 |
| Amgen | 5 | $85 |
| E.r. Squibb & Sons, L.L.C. | 2 | $66 |
| AstraZeneca | 3 | $51 |
| Xeris Pharmaceuticals, Inc. | 2 | $45 |
| Lilly USA, LLC | 2 | $35 |
| Aurinia Pharma U.S., Inc. | 2 | $33 |
| Johnson & Johnson | 2 | $31 |
| Exact Sciences | 2 | $31 |
| Bristol Myers Squibb | 1 | $24 |
| UCB, Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $15 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $13 |
How this compares
$903 in reported general payments places this provider in the 25th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 13 | $97,986 |
| Hydroxychloroquine Sulfate | 73 | $2,001 |
| Leflunomide | 39 | $1,730 |
| MethotrexateMethotrexate Sodium | 82 | $1,295 |
| Sulfasalazine DrSulfasalazine | 17 | $618 |
| Sulfasalazine | 17 | $454 |
| Prednisone | 32 | $173 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Rockwall
- John CushDallas$3.7M
- Sanjay ChabraEl Paso$3.3M
- Dhiman BasuColleyville$1.8M
- Frank WellborneNew Braunfels$1.4M
- Christopher ParkerWest Lake Hills$1.4M
- Pendleton WickershamSan Antonio$954K
- Henry TownsendPlano$738K
- Zoran KurepaDallas$483K
- Giovanni GeslaniDallas$415K
- Dianne PetroneDallas$401K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.